Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nuvalent, Inc. (NUVL : NSDQ)
 
 • Company Description   
Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 142

 
 • Price / Volume Information   
Yesterday's Closing Price: $69.85 Daily Weekly Monthly
20 Day Moving Average: 613,936 shares
Shares Outstanding: 71.60 (millions)
Market Capitalization: $5,001.12 (millions)
Beta: 1.42
52 Week High: $113.51
52 Week Low: $55.54
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 12.68% 4.88%
12 Week -13.71% -6.77%
Year To Date -10.77% -5.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
One Broadway 14thFloor
-
Cambridge,MA 02142
USA
ph: 857-357-7000
fax: -
clister@nuvalent.com http://www.nuvalent.com
 
 • General Corporate Information   
Officers
James R. Porter - Chief Executive Officer; President and Director
Alexandra Balcom - Chief Financial Officer and Treasurer
Deborah Miller - Chief Legal Officer and Secretary
Grant Bogle - Director
Emily Drabant Conley - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 670703107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 71.60
Most Recent Split Date: (:1)
Beta: 1.42
Market Capitalization: $5,001.12 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.66
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -71.01%
vs. Previous Quarter: -12.38%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/25 - -31.92
12/31/24 - -29.77
09/30/24 - -28.63
ROA
03/31/25 - -30.03
12/31/24 - -28.08
09/30/24 - -27.15
Current Ratio
03/31/25 - -
12/31/24 - 20.96
09/30/24 - 23.07
Quick Ratio
03/31/25 - -
12/31/24 - 20.96
09/30/24 - 23.07
Operating Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Net Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Pre-Tax Margin
03/31/25 - -
12/31/24 - -
09/30/24 - -
Book Value
03/31/25 - -
12/31/24 - 14.99
09/30/24 - 15.81
Inventory Turnover
03/31/25 - -
12/31/24 - -
09/30/24 - -
Debt-to-Equity
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©